

3.3. IMPACT

3.3.1. Influence on decisions of key immunization stakeholders

- Question 1: Have SAGE recommendations influenced or triggered decisions and/or did they have an impact on the implementation of activities of key stakeholders? Specify below:

Stakeholder	Influence on Decision	Impact on Implementation
WHO HQ	<p>Shapes WHO's vaccine recommendations in the form of vaccine position papers and other WHO guidance documents; 29 vaccine-related VPP's have been issued based on SAGE rec's between 2012 – 2018</p> <p>Decisions on overall immunization strategies (GVAP): One overall strategy endorsement and 6 assessment reports (incl 2018)</p> <p>Published WHO technical guidance on polio (6) and measles/rubella (4)</p> <p>Published WHO technical guidance on emergencies (diseases specific): Ebola (2); influenza pandemic (1), smallpox (1)</p> <p>WHO technical guidance on programmatic issues: vaccine hesitancy; missed opportunities for vaccination, reducing pain and distress at the time of vaccination session (VPP)</p>	<p>Shapes priorities and strategies related to WHO immunization work</p> <p>VPP's have been triggering vaccine introduction activities, policy choices, schedule changes (simplification), fractional dose use and more</p> <p>GVAP serves as overall multipartner immunization strategy, M&E framework implemented, assessment reports have provided guidance on corrective actions, WHA endorsement</p> <p>Various key adjustments to policy, e.g. OPV – IPV switch, OPV3 cessation</p> <p>Immunization for use of experimental Ebola vaccine, stockpile and vaccine use recommendations (smallpox, H5N1)</p> <p>Detailed technical guidance (journal), WHO strategy on missed opportunities, position paper</p>
WHO RO	<p>RITAG agendas comprise an update of recent SAGE recommendations, VPP's of particular relevance are discussed in context of regional priorities (examples influenza, typhoid in AFRO; dengue in AMRO)</p>	<p>Shapes priorities and implementation strategies;</p> <p>AFRO: recommendation on targeted strategies for influenza/typhoid; AMRO: no recommendation for introduction of dengue at that stage</p>

WHO CO	VPP's are being communicated to countries, follow-up with EPI managers	WHO supports establishment and functioning of NITAGs to do informed decision-making at country level
Countries' relevant Ministers (HIC)	Influences country decisions for selected diseases (e.g., IHR- related diseases - polio containment, influenza, etc.)	Yellow-fever one dose for life strategy implemented in most countries;
Countries' relevant Ministers (MIC)	Influences country/NITAG decisions related to vaccine use as a result of WHO vaccine recommendations of the position papers	Country uptake of new vaccines
Countries' relevant Ministers (LIC)	Influences country/NITAG decisions as a result of WHO vaccine recommendations of the position papers	WHO recommendations influence country decisions as well as donor decisions and thus availability of resources for country implementation.
UNICEF PD and other UN implementing agencies (specify)	Influences by providing high-level vaccine and immunization priorities	
UNICEF SD	Influences through WHO vaccine position papers, Vaccine Product Profile, pre-qualification (a WHO VPP is a prerequisite for PQ), e.g., shift from TT procurement to TD	Influences through vaccine demand generated by WHO recommendations, impact on procurement and price
Gavi	Influences Gavi VIS policy and WHO vaccine position papers and recommendations open windows for Gavi new vaccine support	WHO recommendations define vaccination strategies that Gavi will support and resources Gavi makes available for vaccine introduction/SIAs/demonstration projects (HPV, MVIP, malaria)
BMGF	Influences resources allocation, e.g. for polio research & development; needs articulated by SAGE (e.g., for data on rotavirus vaccine efficacy in different settings, typhoid demonstration) can also shape resources available for R&D for other vaccines	
Implementing NGOs (specify)		MSF follows WHO recommendations for vaccine use in emergencies
CSOs (specify)	WHO endorsement of progress/strategy related to polio Influences Rotary resources/willingness to support	
Manufacturers (specify)	WHO recommendations influence manufacturers' work related to product specifications, product development (Ebola vaccine development, IPV needs, bivalent and monovalent OPV formulations), supply and presentation	

Research agencies (specify)	Questions posed by SAGE sometimes influence research work of PATH or NIH, GVAP triggered a collaborative action between BMGF, NIAID and WHO	
Academics (specify)	Questions posed by SAGE sometimes influence research work of LSHTM, Johns Hopkins, commissioned studies	
Other health agencies (specify)	USAID, JICO, NORAD, others possibly influenced to support certain country programmatic needs based on SAGE-identified needs/recommendations/strategies for countries (workforce, cold chain)	
Others (specify)	Many professional associations are influenced by SAGE recommendations	